StockData
Celularity Inc logo

Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.57−0.05 (-7.75%)

Close on Nov 17, 2026Market cap $18.53MP/E –Yield –

Celularity r&d expenses

Research and development expenses are spending on new products and technology.

Celularity's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.97M, down 12.5% year over year. For fiscal 2025 it was $15.03M, down 13.6% from the year before. The highest annual figure on record is $88.35M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.03M-13.6%
FY2024Dec 31, 2024$17.39M-42.9%
FY2023Dec 31, 2023$30.47M-61.1%
FY2022Dec 31, 2022$78.36M-11.3%
FY2021Dec 31, 2021$88.35M+67.6%
FY2020Dec 31, 2020$52.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.03M-39.5%
Q1 FY2026Mar 31, 2026$2.99M-19.7%
Q4 FY2025Dec 31, 2025$3.35M-12.6%
Q3 FY2025Sep 30, 2025$4.60M+17.4%
Q2 FY2025Jun 30, 2025$3.35M-11.8%
Q1 FY2025Mar 31, 2025$3.73M-36.2%
Q4 FY2024Dec 31, 2024$3.83M-26.1%
Q3 FY2024Sep 30, 2024$3.92M-54.5%
Q2 FY2024Jun 30, 2024$3.80M-77.6%
Q1 FY2024Mar 31, 2024$5.84M-46.8%
Q3 FY2023Sep 30, 2023$5.18M-74.5%
Q2 FY2023Jun 30, 2023$8.60M-66.1%
Q1 FY2023Mar 31, 2023$16.95M-21.8%
Q4 FY2022Dec 31, 2022$10.99M-55.5%
Q3 FY2022Sep 30, 2022$20.35M-14.4%
Q2 FY2022Jun 30, 2022$25.35M+10.6%
Q1 FY2022Mar 31, 2022$21.67M+27.6%
Q4 FY2021Dec 31, 2021$24.69M+77.3%
Q3 FY2021Sep 30, 2021$23.77M+111.9%
Q2 FY2021Jun 30, 2021$22.91M–
Q1 FY2021Mar 31, 2021$16.99M–
Q4 FY2020Dec 31, 2020$13.92M–
Q3 FY2020Sep 30, 2020$11.22M–

More Celularity figures

See a number that looks wrong?